Publications

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Download PDF
Resource: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

.

Related Articles

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Link
EWS::WT1 Isoform-Dependent Regulation of Neogenes in Desmoplastic Small Round Cell Tumors

Link